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SUMMARY. The objective of reducing analysis time and maintaining good efficiency, there has been sub-
stantial focus on high-speed chromatographic separations. Recently, commercially available ultra perfor-
mance liquid chromatography (UPLC) has proven to be one of the most promising developments in the
area of fast chromatographic separations. In this work, a new isocratic reverse phase chromatographic
stability indicating assay method was developed using UPLC for salmeterol xinafoate bulk drug. A novel
stability-indicating UPLC assay method was developed and validated for salmeterol xinafoate and its
degradation products. An isocratic UPLC method was developed to separate the drug from the degrada-
tion products, using an Acquity UPLC BEH C18 (50 mm x 2.1 mm column). Mixture of methanol: 0.06 %
and pH 3.4 ammonium acetate (65:35) was used as mobile phase. The flow rate was kept 0.6 mL/min and
the detection was carried out at 228 nm. The linearity of the proposed method was investigated in the
range of 10-50 μg/mL (r2 = 0.999) for salmeterol xinafoate. The method detection limit was 0.5 μg/mL and
the method quantification limit was 1 μg/mL. The percentage recovery of salmeterol xinafoate was ranged
from 97.2 to 99.5 %. The %RSD values for intra-day precision study were <1.0 % and for inter-day study
were < 2.0 %, confirming that the method was sufficiently precise. The validation studies were carried out
fulfilling International Conference on Harmonisation (ICH) requirements. The procedure was found to be
specific, linear, precise (including intra and inter day precision), accurate and robust.
